LEHI, Utah, June 15, 2026
Halia Therapeutics has announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to ofirnoflast (HT-6184) for the treatment of adult patients with lower-risk myelodysplastic syndromes (LR-MDS). The designation follows encouraging Phase 2 clinical trial results demonstrating durable transfusion independence, multilineage hematologic improvement, and a favorable safety profile in patients with limited treatment options. The regulatory milestone strengthens the development pathway for the company’s lead investigational therapy and highlights the growing importance of targeting inflammasome-driven disease biology in hematologic disorders.
Phase 2 Trial Demonstrates Strong Hematologic Responses
The FDA’s Fast Track designation was supported by data from an open-label, single-arm Phase 2 study involving 37 adults with lower-risk MDS who had symptomatic anemia or red blood cell transfusion dependence and were refractory to, intolerant of, or ineligible for erythropoiesis-stimulating agents. Patients received ofirnoflast 2 mg orally once daily on a five-days-on, two-days-off schedule for up to 32 weeks.
Among the 30 evaluable patients, the study reported a 67% overall best on-study hematologic improvement (HI) rate, demonstrating broad activity across multiple blood cell lineages. Hematologic improvement was observed in erythroid, platelet, and neutrophil responses, highlighting the drug’s potential to address the complex bone marrow dysfunction associated with MDS. Of the 18 transfusion-dependent patients enrolled, 56% achieved red blood cell transfusion independence for at least eight weeks, with a median duration of 28 weeks. Notably, nearly 40% of responders maintained transfusion independence for at least 16 weeks. In non-transfusion-dependent patients, 75% achieved erythroid improvement, while responders experienced a median peak hemoglobin increase of 4.6 g/dL, indicating clinically meaningful improvements in anemia.
Novel NEK7 Modulation Targets Underlying Disease Biology
Advertisement
Ofirnoflast represents a first-in-class oral therapy designed to modulate NEK7, a key regulator of the NLRP3 inflammasome, which plays a critical role in chronic inflammation and ineffective hematopoiesis in lower-risk MDS. Unlike therapies that primarily manage symptoms, ofirnoflast is designed to target an underlying biological driver of disease progression.
Activation of the NLRP3 inflammasome contributes to bone marrow dysfunction, impaired blood cell production, and chronic anemia in patients with MDS. By preventing inflammasome assembly and promoting its disassembly, ofirnoflast aims to reduce inflammatory signaling and restore healthier hematopoietic function. Importantly, clinical activity was observed across multiple World Health Organization MDS subtypes and was reported to be mutation agnostic, including patients with and without SF3B1 mutations or del(5q) abnormalities. These findings suggest the therapy may have broad applicability across diverse patient populations.
FDA Fast Track Designation Accelerates Development Pathway
The FDA’s Fast Track designation is intended to facilitate the development and review of therapies addressing serious conditions with significant unmet medical needs. Companies receiving Fast Track status benefit from increased communication with the FDA and may qualify for additional regulatory advantages, including Rolling Review, Priority Review, and potential Accelerated Approval pathways if eligibility criteria are met.
The Phase 2 study also demonstrated a favorable safety profile. No treatment-related serious adverse events were reported, while treatment-related adverse events were primarily mild to moderate in severity. Grade 3 or higher treatment-related adverse events occurred in only a small percentage of patients, supporting continued clinical advancement.
Halia Therapeutics is now preparing the next phase of development for ofirnoflast and intends to leverage the benefits associated with Fast Track designation as it advances toward pivotal studies. With lower-risk MDS patients frequently facing chronic anemia, transfusion dependence, and limited therapeutic options after failure of currently available treatments, the company believes ofirnoflast could emerge as a promising new oral treatment option capable of addressing both disease biology and patient quality of life.
Source: Halia Therapeutics press release
